Scholar Rock Holding Corporation (SRRK)

13,85 -0,10 (-0,72%) Al cierre: 04:00PM EDT

Scholar Rock Holding Corporation

301 Binney Street
3rd Floor
Cambridge, MA 02142
United States
857 259 3860
https://scholarrock.com

Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 150

Ejecutivos clave

Nombre	Título	Paga	Ejecutado	Año de nacimiento
Dr. Jay Thomas Backstrom M.D., M.P.H.	President, CEO & Director	686,49k	N/A	1955
Mr. Edward H. Myles MBA	CFO, COO & Treasurer	668,49k	N/A	1972
Ms. Junlin Ho J.D.	General Counsel & Corporate Secretary	563,73k	N/A	1979
Mr. Mo Qatanani Ph.D.	Chief Scientific Officer	N/A	N/A	1974
Rushmie Nofsinger	Vice President of Corporate Affairs & Investor Relations	N/A	N/A	N/A
Ms. Caryn Parlavecchio	Chief Human Resources Officer	N/A	N/A	1972
Ms. Lisa Amaya Price	Senior Vice President of Human Resources	N/A	N/A	N/A
Ms. Erin Moore	Senior Vice President of Finance	N/A	N/A	1975
Mr. Ryan Iarrobino	Senior Vice President of Clinical Development & Operations	N/A	N/A	N/A
Dr. Jing L. Marantz M.B.A., M.D., Ph.D.	Chief Medical Officer	N/A	N/A	1965

Los importes son a partir de 31 de diciembre de 2022 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.

Gobierno corporativo

El ISS Governance QualityScore de Scholar Rock Holding Corporation, a día 1 de abril de 2024, es 7. Las puntuaciones base son Auditoría: 3; Tablero: 7; Derechos de los accionistas: 8; Compensación: 9.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.